Thank you.
I'm going to focus on the drug side of the equation for the three minutes I have.
My question relates to the signal that we seem to be getting from CETA. As it relates to your industry, it seems that the negotiators walked a fine line by providing something to both sides, both the innovators and the generics.
For the innovators, you got two years' extra patent protection, and for the generics, they got an end to dual litigation. Is this not a fair balance? Is this not a way of walking that fine line—not harming one side of the industry or the other side of the industry?